ClinicalTrials.gg

Program

Actinium Ac 225-ETN029

In Novartis’s pipeline, Radioligand therapy target DLL3. Its studies are mostly in Small Cell Lung Carcinoma, led by Novartis.

Furthest: phase 1, since May 16, 20251 company-led study, 1 open or runningNext primary completion: Aug 29, 2031 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis11 open or runningphase 1since May 16, 2025May 16, 2025Aug 29, 2031phase 1 · NCT07006727
  • Named in Novartis’s own pipeline as ESP359 (225Ac-ETN029), phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 16, 2025First study: phase 1 study in Small Cell Lung CarcinomaFirst studyNCT07006727 · 116 planned · United States, Canada, Japan and more

Ahead

  1. Aug 29, 2031Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT07006727

TargetBeta

“Radioligand therapy target DLL3”the company's pipeline, read by Claude · source

Other programs on DLL3

ProgramCompanyFurthest phaseStudies
tarlatamabruleAmgenphase 313
AlveltamigruleSuzhou Zelgen Biopharmaceuticalsphase 311
obrixtamigBoehringer Ingelheimphase 311
Zocilurtatug PelitecanruleZai Labphase 36
Anti-DLL3 Antibody-drug Conjugate BL-M14D1Sichuan Biokin Pharmaceuticalphase 34
gocatamigMerckphase 34
Autologous Anti-DLL3 CAR-T Cells DJI136Novartisphase 22
Anti-DLL3 Antibody-drug Conjugate IDE849ideaya-biosciencesphase 22
SHR-7787Jiangsu HengRui Medicinephase 21
Anti-DLL3 Antibody-drug Conjugate FZ-AD005ruleShanghai Fudan-Zhangjiang Bio-Pharmaceuticalphase 12
clesitamigHoffmann-La Rochephase 12
Actinium Ac 225-ABD147ruleabdera-therapeutics-incphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07006727Small Cell Lung Carcinoma · United States, Canada, Japan and more1RecruitingAug 29, 2031116

How it is read

Names in the registry

  • “225Ac-ETN029”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.